Nerites
Founded Year
2004Stage
Acquired | AcquiredTotal Raised
$5.7MValuation
$0000About Nerites
Nerites is developing a new generation of synthetic coating and surgical adhesive biomaterials that can enhance natural tissue repair, reduce complications from traditional devices and degrade safely when they are no longer needed.
Loading...
Loading...
Nerites Patents
Nerites has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/6/2007 | 11/24/2009 | Adhesives, Polymers, Beta blockers, Polymer chemistry, Thermoplastics | Grant |
Application Date | 8/6/2007 |
|---|---|
Grant Date | 11/24/2009 |
Title | |
Related Topics | Adhesives, Polymers, Beta blockers, Polymer chemistry, Thermoplastics |
Status | Grant |
Latest Nerites News
Dec 2, 2016
NERITES Corporation, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 20:20 EST 1 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » NERITES Corporation, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' NERITES Corporation, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by NERITES Corporation, Inc. since January 2007. Key Findings Provides intelligence on NERITES Corporation, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by NERITES Corporation, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for NERITES Corporation, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about NERITES Corporation, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Nerites Frequently Asked Questions (FAQ)
When was Nerites founded?
Nerites was founded in 2004.
Where is Nerites's headquarters?
Nerites's headquarters is located at 525 Science Drive, Madison.
What is Nerites's latest funding round?
Nerites's latest funding round is Acquired.
How much did Nerites raise?
Nerites raised a total of $5.7M.
Who are the investors of Nerites?
Investors of Nerites include Kensey Nash, Venture Investors, Wisconsin Investment Partners, Northwestern University and MGE Innovation Center.
Who are Nerites's competitors?
Competitors of Nerites include Regentis Biomaterials, Histogenics, NextWave Pharmaceuticals, Juventas Therapeutics, PrevaCept Infection Control and 7 more.
Loading...
Compare Nerites to Competitors
SyntheMed, Inc. is a biomaterials company dedicated to developing and marketing proprietary polymer products used to prevent or reduce adhesions that may form in a a broad range of surgical procedures.
EnvirGen, Inc. is a provider of R&D in nutraceutical/pharmaceutical products that help cardiovascular, gastrointestinal, and liver health. The company uses natural and synthetic compound screening to develop natural and safe solutions for public health.
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.
AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.
FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.
Loading...